Bipolar Disorders and Treatment Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Market Dynamics of Bipolar Disorders and Treatment Market Analysis

Growth Drivers

  • The increase in the prevalence of bipolar disorder is driving the growth of the bipolar disorder Market.
  • Immediate approval of bipolar disorder therapeutics by regulatory authorities drives the bipolar disorder market.  

Restraints

  • Side effects associated with drugs restrain the bipolar disorder market.  

Trends

  • The development of innovative bipolar disorder treatments represents a significant opportunity for the automotive industry.  

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Bipolar Disorders and Treatment Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Bipolar Disorders and Treatment Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxx$ 6902.44 Million3.5%
North Americaxxxxxxxxxxxxxxxx
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxxxxxx
United Kingdomxxxxxxxxxxxxxxxx
Francexxxxxxxxxxxxxxxx
Germanyxxxxxxxxxxxxxxxx
Italyxxxxxxxxxxxxxxxx
Russiaxxxxxxxxxxxxxxxx
Spainxxxxxxxxxxxxxxxx
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourgxxxxxxxxxxxxxxxx
Rest of Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxxxxxx
Chinaxxxxxxxxxxxxxxxx
Japanxxxxxxxxxxxxxxxx
South Koreaxxxxxxxxxxxxxxxx
Indiaxxxxxxxxxxxxxxxx
Australiaxxxxxxxxxxxxxxxx
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asiaxxxxxxxxxxxxxxxx
Rest of APACxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxxxxxx
Brazilxxxxxxxxxxxxxxxx
Argentinaxxxxxxxxxxxxxxxx
Colombiaxxxxxxxxxxxxxxxx
Peruxxxxxxxxxxxxxxxx
Chilexxxxxxxxxxxxxxxx
Rest of South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxxxxxx
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxxxxxx
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxxxxxx
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Segment Performance in The Bipolar Disorder Treatment Market Drug Class Segment Analysis The anti-psychotic Drugs segment holds the largest market share. This is due to the increasing prevalence of bipolar disorder. Antipsychotic medications were originally utilized in psychiatric therapy to treat acute episodes of bipolar illness and prevent relapses. The effectiveness of this family of medications to treat manic depression has drawn renewed attention with the introduction of second-generation antipsychotics, increasing their market share. Anti-psychotics are commonly used as maintenance therapy to prevent relapses and stabilize mood fluctuations in both Bipolar I and Bipolar II disorders. Their efficacy in managing a broad spectrum of symptoms makes them indispensable in the treatment landscape. Moreover, ongoing research and development efforts have led to the introduction of newer-generation anti-psychotics with improved tolerability and fewer side effects, further driving their adoption. Overall, the widespread use, effectiveness across symptom domains, and continuous innovation in anti-psychotic medications solidify their position as the leading segment in the bipolar disorder market. For instance, in December 2021, Zydus Cadila got the United States Food and Drug Administration (USFDA) approval to market generic drug Cariprazine capsules, which are used in the treatment of schizophrenia. Source:(https://www.business-standard.com/article/companies/zydus-cadila-gets-usfda-approval-to-market-generic-schizophrenia-drug-121121100071_1.html)

Mood Stabilizer Bipolar Disorders and Treatment Market Analysis
XX
Mood Stabilizer Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Anticonvulsants Bipolar Disorders and Treatment Market Analysis
XX
Anticonvulsants Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Anti-Psychotic Drugs Bipolar Disorders and Treatment Market Analysis
XX
Anti-Psychotic Drugs Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Anti-Depressant Drugs Bipolar Disorders and Treatment Market Analysis
XX
Anti-Depressant Drugs Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Anti-Anxiety Drugs Bipolar Disorders and Treatment Market Analysis
XX
Anti-Anxiety Drugs Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape: The Bipolar Disorder Treatment Market

The bipolar disorder market is highly competitive and somewhat fragmented worldwide. To stay afloat in the industry, the major businesses functioning in it regularly use different development methods. These major competitors use a variety of growth methods to survive in the cutthroat industry, including product launches, inventions, mergers and acquisitions, partnerships and collaborations, and extensive research and development. The major market players are also always concentrating on research and development to provide the most economical and effective solutions to industries. 
For instance, in June 2023, Brain Therapeutics, a Greece-based central nervous system specialty company, acquired the prescription drug brand Lazap (olanzapine) from the Greek pharmaceutical company Lyofin Ltd for an undisclosed amount. The acquisition enables Neuraxpharm Group to expand its therapeutic product portfolio in Greece and Europe. This agreement aims to extend Neuraxpharm's reach in Greece and harness its deep expertise in the central nervous system (CNS) to offer the right products from its extensive lineup to CNS patients, healthcare professionals, pharmacists, and hospitals across Greece, effectively meeting the healthcare demands of patients in the country. Lyofin Ltd. is a Greece-based pharmaceutical company.
Source:(https://www.neuraxpharm.com/media/neuraxpharm-expands-greek-product-portfolio-with-acquisition-of-lazap-a-well-established-antipsychotic-brand)
 

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Allergan••• ••• ••• •••
AstraZeneca plc••• ••• ••• •••
Bristol Myers Squibb Company••• ••• ••• •••
Eli Lilly and Company••• ••• ••• •••
GlaxoSmithKline plc••• ••• ••• •••
H. Lundbeck A/S••• ••• ••• •••
Janssen Pharmaceuticals Inc.••• ••• ••• •••
Otsuka Holdings Co. Ltd.••• ••• ••• •••
Pfizer Inc.••• ••• ••• •••
Sunovion Pharmaceuticals Inc.••• ••• ••• •••
Teva Pharmaceutical Industries Ltd.••• ••• ••• •••
Takeda Pharmaceutical Company Limited••• ••• ••• •••
Abbott Laboratories••• ••• ••• •••
Novartis International AG••• ••• ••• •••
Alkermes plc••• ••• ••• •••
AbbVie Inc.••• ••• ••• •••
Merck & Co. Inc.••• ••• ••• •••
Mylan N.V.••• ••• ••• •••
Neurocrine Biosciences Inc.••• ••• ••• •••
Vanda Pharmaceuticals Inc.••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis


According to Cognitive Market Research, The Bipolar Disorder Treatment Market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. 
North America held the major market share for more than XX% of the global revenue with a market size of USD XX  million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Europe region is the fastest growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Asia Pacific accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Bipolar Disorder Treatment Market held the highest market revenue share in 2024.

Introduction of The Bipolar Disorder Treatment Market

Bipolar disorder (formerly called manic-depressive illness or manic depression) is a mental illness that causes unusual shifts in a person's mood, energy, activity levels, and concentration. These shifts can make it difficult to carry out day-to-day tasks. There are three types of bipolar disorder. All three types involve clear changes in mood, energy, and activity levels. These moods range from periods of extremely “up,” elated, irritable, or energized behavior (known as manic episodes) to very “down,” sad, indifferent, or hopeless periods (known as depressive episodes). Less severe manic periods are known as hypomanic episodes.
Bipolar I disorder is defined by manic episodes that last for at least 7 days (nearly every day for most of the day) or by manic symptoms that are so severe that the person needs immediate medical care. Usually, depressive episodes occur as well, typically lasting at least 2 weeks. Episodes of depression with mixed features (having depressive symptoms and manic symptoms at the same time) are also possible. Experiencing four or more episodes of mania or depression within 1 year is called “rapid cycling.”
Bipolar II disorder is defined by a pattern of depressive episodes and hypomanic episodes. The hypomanic episodes are less severe than the manic episodes in bipolar I disorder.
Cyclothymic disorder (also called cyclothymia) is defined by recurring hypomanic and depressive symptoms that are not intense enough or do not last long enough to qualify as hypomanic or depressive episodes.
The growing incidence of bipolar illness, government initiatives, the development of the healthcare infrastructure, and the rising popularity of sedentary lifestyles are all contributing factors to the rise observed throughout the predicted period. Personalized treatment strategies, the integration of digital health, novel drugs, preventative measures, neuroimaging, and biomarkers are key themes for the predicted period.

Analyst Conclusion

With the help of the above study about the Bipolar Disorder Treatment Market, it can be concluded that the market for Bipolar Disorder Treatment worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Bipolar Disorders and Treatment Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers Allergan, AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc. and others are profiled in the report.
Segments include Drug Class, Distribution Channel and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Bipolar Disorders and Treatment Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Drug ClassMood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, Anti-Anxiety Drugs
Distribution ChannelHospital Pharmacies, Retail Pharmacies, Online Pharmacies
Bipolar DisorderBipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder
List of CompetitorsAllergan, AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc.

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Bipolar Disorders and Treatment Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Allergan
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 AstraZeneca plc
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 Financials (Subject to data availability)
        • 1.2.2.4 R&D Investment (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Bristol Myers Squibb Company
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 Financials (Subject to data availability)
        • 1.2.3.4 R&D Investment (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Eli Lilly and Company
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 Financials (Subject to data availability)
        • 1.2.4.4 R&D Investment (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 GlaxoSmithKline plc
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 Financials (Subject to data availability)
        • 1.2.5.4 R&D Investment (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 H. Lundbeck A/S
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 Financials (Subject to data availability)
        • 1.2.6.4 R&D Investment (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 Janssen Pharmaceuticals Inc.
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 Financials (Subject to data availability)
        • 1.2.7.4 R&D Investment (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 Otsuka Holdings Co. Ltd.
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 Financials (Subject to data availability)
        • 1.2.8.4 R&D Investment (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Pfizer Inc.
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 Financials (Subject to data availability)
        • 1.2.9.4 R&D Investment (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Sunovion Pharmaceuticals Inc.
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 Financials (Subject to data availability)
        • 1.2.10.4 R&D Investment (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Teva Pharmaceutical Industries Ltd.
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 Financials (Subject to data availability)
        • 1.2.11.4 R&D Investment (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis
      • 1.2.12 Takeda Pharmaceutical Company Limited
        • 1.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.12.2 Business Overview
        • 1.2.12.3 Financials (Subject to data availability)
        • 1.2.12.4 R&D Investment (Subject to data availability)
        • 1.2.12.5 Product Types Specification
        • 1.2.12.6 Business Strategy
        • 1.2.12.7 Recent Developments
        • 1.2.12.8 Management Change
        • 1.2.12.9 S.W.O.T Analysis
      • 1.2.13 Abbott Laboratories
        • 1.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.13.2 Business Overview
        • 1.2.13.3 Financials (Subject to data availability)
        • 1.2.13.4 R&D Investment (Subject to data availability)
        • 1.2.13.5 Product Types Specification
        • 1.2.13.6 Business Strategy
        • 1.2.13.7 Recent Developments
        • 1.2.13.8 Management Change
        • 1.2.13.9 S.W.O.T Analysis
      • 1.2.14 Novartis International AG
        • 1.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.14.2 Business Overview
        • 1.2.14.3 Financials (Subject to data availability)
        • 1.2.14.4 R&D Investment (Subject to data availability)
        • 1.2.14.5 Product Types Specification
        • 1.2.14.6 Business Strategy
        • 1.2.14.7 Recent Developments
        • 1.2.14.8 Management Change
        • 1.2.14.9 S.W.O.T Analysis
      • 1.2.15 Alkermes plc
        • 1.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.15.2 Business Overview
        • 1.2.15.3 Financials (Subject to data availability)
        • 1.2.15.4 R&D Investment (Subject to data availability)
        • 1.2.15.5 Product Types Specification
        • 1.2.15.6 Business Strategy
        • 1.2.15.7 Recent Developments
        • 1.2.15.8 Management Change
        • 1.2.15.9 S.W.O.T Analysis
      • 1.2.16 AbbVie Inc.
        • 1.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.16.2 Business Overview
        • 1.2.16.3 Financials (Subject to data availability)
        • 1.2.16.4 R&D Investment (Subject to data availability)
        • 1.2.16.5 Product Types Specification
        • 1.2.16.6 Business Strategy
        • 1.2.16.7 Recent Developments
        • 1.2.16.8 Management Change
        • 1.2.16.9 S.W.O.T Analysis
      • 1.2.17 Merck & Co. Inc.
        • 1.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.17.2 Business Overview
        • 1.2.17.3 Financials (Subject to data availability)
        • 1.2.17.4 R&D Investment (Subject to data availability)
        • 1.2.17.5 Product Types Specification
        • 1.2.17.6 Business Strategy
        • 1.2.17.7 Recent Developments
        • 1.2.17.8 Management Change
        • 1.2.17.9 S.W.O.T Analysis
      • 1.2.18 Mylan N.V.
        • 1.2.18.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.18.2 Business Overview
        • 1.2.18.3 Financials (Subject to data availability)
        • 1.2.18.4 R&D Investment (Subject to data availability)
        • 1.2.18.5 Product Types Specification
        • 1.2.18.6 Business Strategy
        • 1.2.18.7 Recent Developments
        • 1.2.18.8 Management Change
        • 1.2.18.9 S.W.O.T Analysis
      • 1.2.19 Neurocrine Biosciences Inc.
        • 1.2.19.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.19.2 Business Overview
        • 1.2.19.3 Financials (Subject to data availability)
        • 1.2.19.4 R&D Investment (Subject to data availability)
        • 1.2.19.5 Product Types Specification
        • 1.2.19.6 Business Strategy
        • 1.2.19.7 Recent Developments
        • 1.2.19.8 Management Change
        • 1.2.19.9 S.W.O.T Analysis
      • 1.2.20 Vanda Pharmaceuticals Inc.
        • 1.2.20.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.20.2 Business Overview
        • 1.2.20.3 Financials (Subject to data availability)
        • 1.2.20.4 R&D Investment (Subject to data availability)
        • 1.2.20.5 Product Types Specification
        • 1.2.20.6 Business Strategy
        • 1.2.20.7 Recent Developments
        • 1.2.20.8 Management Change
        • 1.2.20.9 S.W.O.T Analysis

  • Chapter 2. Global Bipolar Disorders and Treatment Market Analysis

    • 2.1 Global Bipolar Disorders and Treatment Market Analysis
    • 2.2 Global Bipolar Disorders and Treatment Market Analysis by Region
    • 2.3 Global Bipolar Disorders and Treatment Market Analysis by Drug Class
    • 2.4 Global Bipolar Disorders and Treatment Market Analysis by Distribution Channel
    • 2.5 Global Bipolar Disorders and Treatment Market Analysis by Bipolar Disorder
    • 2.6 Global Bipolar Disorders and Treatment Market Analysis by Key Players

  • Chapter 3. North America Bipolar Disorders and Treatment Market Analysis

    • 3.1 North America Bipolar Disorders and Treatment Market Analysis
    • 3.2 North America Bipolar Disorders and Treatment Market Analysis by Country
    • 3.3 North America Bipolar Disorders and Treatment Market Analysis by Drug Class
    • 3.4 North America Bipolar Disorders and Treatment Market Analysis by Distribution Channel
    • 3.5 North America Bipolar Disorders and Treatment Market Analysis by Bipolar Disorder
    • 3.6 North America Bipolar Disorders and Treatment Market Analysis by Key Players

  • Chapter 4. Europe Bipolar Disorders and Treatment Market Analysis

    • 4.1 Europe Bipolar Disorders and Treatment Market Analysis
    • 4.2 Europe Bipolar Disorders and Treatment Market Analysis by Country
    • 4.3 Europe Bipolar Disorders and Treatment Market Analysis by Drug Class
    • 4.4 Europe Bipolar Disorders and Treatment Market Analysis by Distribution Channel
    • 4.5 Europe Bipolar Disorders and Treatment Market Analysis by Bipolar Disorder
    • 4.6 Europe Bipolar Disorders and Treatment Market Analysis by Key Players

  • Chapter 5. Asia Pacific Bipolar Disorders and Treatment Market Analysis

    • 5.1 Asia Pacific Bipolar Disorders and Treatment Market Analysis
    • 5.2 Asia Pacific Bipolar Disorders and Treatment Market Analysis by Country
    • 5.3 Asia Pacific Bipolar Disorders and Treatment Market Analysis by Drug Class
    • 5.4 Asia Pacific Bipolar Disorders and Treatment Market Analysis by Distribution Channel
    • 5.5 Asia Pacific Bipolar Disorders and Treatment Market Analysis by Bipolar Disorder
    • 5.6 Asia Pacific Bipolar Disorders and Treatment Market Analysis by Key Players

  • Chapter 6. South America Bipolar Disorders and Treatment Market Analysis

    • 6.1 South America Bipolar Disorders and Treatment Market Analysis
    • 6.2 South America Bipolar Disorders and Treatment Market Analysis by Country
    • 6.3 South America Bipolar Disorders and Treatment Market Analysis by Drug Class
    • 6.4 South America Bipolar Disorders and Treatment Market Analysis by Distribution Channel
    • 6.5 South America Bipolar Disorders and Treatment Market Analysis by Bipolar Disorder
    • 6.6 South America Bipolar Disorders and Treatment Market Analysis by Key Players

  • Chapter 7. Middle East Bipolar Disorders and Treatment Market Analysis

    • 7.1 Middle East Bipolar Disorders and Treatment Market Analysis
    • 7.2 Middle East Bipolar Disorders and Treatment Market Analysis by Country
    • 7.3 Middle East Bipolar Disorders and Treatment Market Analysis by Drug Class
    • 7.4 Middle East Bipolar Disorders and Treatment Market Analysis by Distribution Channel
    • 7.5 Middle East Bipolar Disorders and Treatment Market Analysis by Bipolar Disorder
    • 7.6 Middle East Bipolar Disorders and Treatment Market Analysis by Key Players

  • Chapter 8. Africa Bipolar Disorders and Treatment Market Analysis

    • 8.1 Africa Bipolar Disorders and Treatment Market Analysis
    • 8.2 Africa Bipolar Disorders and Treatment Market Analysis by Country
    • 8.3 Africa Bipolar Disorders and Treatment Market Analysis by Drug Class
    • 8.4 Africa Bipolar Disorders and Treatment Market Analysis by Distribution Channel
    • 8.5 Africa Bipolar Disorders and Treatment Market Analysis by Bipolar Disorder
    • 8.6 Africa Bipolar Disorders and Treatment Market Analysis by Key Players

  • Chapter 9. Drug Class Analysis

    • 9.1 Mood Stabilizer
      • 9.1.1 Global Mood Stabilizer Market
      • 9.1.2 Global Mood Stabilizer Market by Region
    • 9.2 Anticonvulsants
      • 9.2.1 Global Anticonvulsants Market
      • 9.2.2 Global Anticonvulsants Market by Region
    • 9.3 Anti-Psychotic Drugs
      • 9.3.1 Global Anti-Psychotic Drugs Market
      • 9.3.2 Global Anti-Psychotic Drugs Market by Region
    • 9.4 Anti-Depressant Drugs
      • 9.4.1 Global Anti-Depressant Drugs Market
      • 9.4.2 Global Anti-Depressant Drugs Market by Region
    • 9.5 Anti-Anxiety Drugs
      • 9.5.1 Global Anti-Anxiety Drugs Market
      • 9.5.2 Global Anti-Anxiety Drugs Market by Region

  • Chapter 10. Distribution Channel Analysis

    • 10.1 Hospital Pharmacies
      • 10.1.1 Global Hospital Pharmacies Market
      • 10.1.2 Global Hospital Pharmacies Market by Region
    • 10.2 Retail Pharmacies
      • 10.2.1 Global Retail Pharmacies Market
      • 10.2.2 Global Retail Pharmacies Market by Region
    • 10.3 Online Pharmacies
      • 10.3.1 Global Online Pharmacies Market
      • 10.3.2 Global Online Pharmacies Market by Region

  • Chapter 11. Bipolar Disorder Analysis

    • 11.1 Bipolar I Disorder
      • 11.1.1 Global Bipolar I Disorder Market
      • 11.1.2 Global Bipolar I Disorder Market by Region
    • 11.2 Bipolar II Disorder
      • 11.2.1 Global Bipolar II Disorder Market
      • 11.2.2 Global Bipolar II Disorder Market by Region
    • 11.3 Cyclothymic Disorder
      • 11.3.1 Global Cyclothymic Disorder Market
      • 11.3.2 Global Cyclothymic Disorder Market by Region

  • Chapter 12. Qualitative Analysis (Subject to Data Availability)

    • 12.1 Market Drivers
    • 12.2 Market Restraints
    • 12.3 Market Trends
    • 12.4 Market Opportunity
    • 12.5 Technological Road Map (Subject to Data Availability)
    • 12.6 Product Life Cycle (Subject to Data Availability)
    • 12.7 Customer and Buyer Behavior Analysis
      • 12.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 12.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 12.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 12.7.4 Pricing, Affordability & Value Perception Analysis
      • 12.7.5 Customer Segmentation & Demand Pattern Analysis
    • 12.8 PESTEL Analysis
      • 12.8.1 Political Factors
      • 12.8.2 Economic Factors
      • 12.8.3 Social Factors
      • 12.8.4 Technological Factors
      • 12.8.5 Legal Factors
      • 12.8.6 Environmental Factors
    • 12.9 Industrial Chain Analysis (Subject to Data Availability)
      • 12.9.1 Industry Chain Analysis
      • 12.9.2 Manufacturing Cost Analysis
      • 12.9.3 Supply Side Analysis
        • 12.9.3.1 Raw Material Analysis
        • 12.9.3.2 Raw Material Procurement Analysis
        • 12.9.3.3 Raw Material Price Trend Analysis
    • 12.10 Porter’s Five Forces Analysis
      • 12.10.1 Bargaining Power of Suppliers
      • 12.10.2 Bargaining Power of Buyers
      • 12.10.3 Threat of New Entrants
      • 12.10.4 Threat of Substitutes
      • 12.10.5 Degree of Competition
    • 12.11 Patent Analysis (Subject to Data Availability)
    • 12.12 ESG Analysis
    • 12.13 Geopolitical Outlook
      • 12.13.1 Global Power Realignment & Strategic Alliances
      • 12.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 12.13.3 International Trade Relations & Market Access Environment
      • 12.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 12.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 12.13.6 Technology Sovereignty & Digital Geopolitics
      • 12.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 12.14 AI & Market Transformation
      • 12.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 12.14.2 AI-Driven Transformation of Industry Value Chain
      • 12.14.3 Evolution of Business Models & Revenue Streams
      • 12.14.4 AI-Driven Product, Service & Innovation Transformation
      • 12.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 13. TOP 10 Country Analysis

    • 13.1 Country 1
    • 13.2 Country 2
    • 13.3 Country 3
    • 13.4 Country 4
    • 13.5 Country 5
    • 13.6 Country 6
    • 13.7 Country 7
    • 13.8 Country 8
    • 13.9 Country 9
    • 13.10 Country 10

  • Chapter 14. Research Findings

    • 14.1 Key Takeaways
    • 14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

  • Chapter 15. Research Methodology and Sources

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Bipolar Disorders and Treatment Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 20+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Bipolar Disorders and Treatment Market

In January 2022, the U.S. Food and Drug Administration (FDA) approved an expanded indication for the antipsychotic Caplyta (lumateperone) for the treatment of bipolar I and II depression in adults. Caplyta, marketed by Intra-Cellular Therapies Inc., was already approved for the treatment of schizophrenia in adults.
Source:(https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar)

In September 2022, Otsuka America Pharmaceutical, Inc., (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the U.S. FDA approved their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults. This approval helped the company to expand its customer base.
Source:(https://www.otsuka-us.com/news/otsuka-and-lundbeck-announce-us-fda-acceptance-new-drug-application-aripiprazole-2-month-ready)

In December 2021, Intra-Cellular Therapies, Inc. confirmed that the U.S. FDA had approved CAPLYTA to treat depressive episodes linked with bipolar I or II disorder in adults, such as monotherapy and adjunctive therapy with valproate or lithium.
Source:(https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar)

 18 Apr 2024 health.economictimes.indiatimes.com

US FDA approves Vandas drug for treatment of bipolar disorder

Fanapt (iloperidone) from Vanda Pharmaceuticals has received FDA approval for the acute management of manic or mixed episodes linked to adult bipolar I illness. Based on the outcomes of a Phase III clinical trial with 400 patients enrolled, the approval was granted. With significant gains evident after two weeks of treatment, the primary goal of a higher success rate than placebo was reached after four weeks. Vanda said that the expanded indication for Fanapt, which was first licenced in 2009 to treat patients with schizophrenia, will give patients variable dosage and a well-established safety profile. In the US, bipolar disorder affects approximately 5.7 million adults, with a 25-year typical onset age. Bipolar disorder may run in families because most persons who are diagnosed with it have a family member who also has the illness or who suffers from severe depression. With this FDA approval, bipolar I disorder management options for patients and service providers are expanded. Based on encouraging findings from two placebo-controlled Phase III clinical trials comparing the medication to active control and placebo in schizophrenia patients, Vanda Pharmaceuticals approved Fanapt for treatment in 2009. Before overturning its earlier judgement, the FDA had denied Vanda's New Drug Application for Fanapt nearly a year earlier.

Read the source

Sources from the Pharma & Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Bipolar Disorders and Treatment Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the bipolar disorders and treatment market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.